More recently, Lelièvre et al. described a lowering of serum vascular endothelial growth factor (VEGF) levels in early BC patients receiving neoadjuvant zoledronate + chemotherapy, even if not statistically significant (p = 0.52), which might be in line with the preclinical evidence of BP anti-angiogenic properties [44,77]. The gene discussed is VEGFA; the disease is breast cancer.